Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Phase 2 Recruiting 96 enrolled Shanghai Pulmonary Hospital, Shanghai, China

RandomizedParallel-groupOpen-labelTreatment

Summary

To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.

Timeline

Start: 2022-02-01
Primary completion: 2023-10-01
Completion: 2028-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	400 mg	Intravenous
Subject	Firmonertinib	Small molecule	80 mg	—

Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Summary

Timeline

Drugs

Indications